DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $12.3333.

Several research firms have recently issued reports on DMAC. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of DMAC. Royal Bank of Canada lifted its stake in DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after buying an additional 154,701 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in DiaMedica Therapeutics by 76.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after buying an additional 52,854 shares during the last quarter. Jane Street Group LLC increased its position in DiaMedica Therapeutics by 138.5% during the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock worth $382,000 after buying an additional 58,457 shares in the last quarter. Geode Capital Management LLC increased its position in DiaMedica Therapeutics by 99.6% during the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after buying an additional 314,407 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of DiaMedica Therapeutics in the second quarter worth $49,000. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Price Performance

NASDAQ DMAC opened at $5.85 on Friday. The business has a 50 day moving average price of $6.06 and a 200 day moving average price of $7.32. The company has a market capitalization of $315.20 million, a P/E ratio of -8.24 and a beta of 0.97. DiaMedica Therapeutics has a 1-year low of $3.47 and a 1-year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its earnings results on Wednesday, May 6th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, research analysts expect that DiaMedica Therapeutics will post -0.86 earnings per share for the current fiscal year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.